Back to search

Article

Effect of levodopa/carbidopa on the progression of Machado-Joseph disease /spinocerebellar ataxia type 3 (MJD/SCA3)

2024-12-03

Abstract excerpt

<h4>Background and Objectives</h4> In Machado-Joseph disease or spinocerebellar ataxia type 3 (MJD/SCA3), ataxin-3 accumulates as neuronal nuclear inclusions in specific regions of the brain such as the substantia nigra and the dentate cerebellar nucleus. Ataxin-3 aggregation is strongly inhibited by dopamine, a neurotransmitter whose brain levels can be increased through the use of medication containing levodopa/...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
8d8a6ce1-d87c-58f9-a968-90d779d6f0b3
DOI
10.1101/2024.11.28.24318145
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Effect of levodopa/carbidopa on the progression of Machado-Joseph disease /spinocerebellar ataxia type 3 (MJD/SCA3)DOI 10.1101/2024.11.28.24318145
Machado Joseph disease: clinical and genetic aspects, and current treatmentSemantic proximity
Initially with pure parkinsonian phenotype of spinocerebellar ataxia type 3: A rare case report and literature reviewSemantic proximity
The Medication Patterns of Spinocerebellar Ataxia Type 3 Mutation Carriers Enrolled in the ESMI Cohort.Semantic proximity
The Medication Patterns of Spinocerebellar Ataxia Type 3 Mutation Carriers Enrolled in the ESMI CohortSemantic proximity
Association between the use of levodopa/carbidopa and the disease outcomes included in the National Alzheimer’s Coordinating Center Uniform Data SetSemantic proximity
Progression of biological markers in spinocerebellar ataxia type 3: analysis of longitudinal data from the ESMI cohortSemantic proximity
Stage‐Dependent Biomarker Changes in Spinocerebellar Ataxia Type 3Semantic proximity
Pharmacological Therapies for Machado-Joseph Disease.Semantic proximity
Modeling disease progression in spinocerebellar ataxiasSemantic proximity
Polyglutamine diseases: The special case of ataxin-3 and Machado–Joseph diseaseSemantic proximity
The progression rate of spinocerebellar ataxia type 2 changes with stage of diseaseSemantic proximity
Antidepressants and Slower Disease Progression in Huntington’s DiseaseSemantic proximity
Select a neighboring publication to make it the new centre.